Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.

<h4>Aims</h4> <p>Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria and the subsequent development of end-stage renal disease (ESRD) in patients with type 2 diabetes. We aimed to examine the effect of valsartan on kidney outcomes in patients...

Full description

Bibliographic Details
Main Authors:	Currie, G, Bethel, M, Holzhauer, B, Haffner, S, Holman, R, McMurray, J
Format:	Journal article
Language:	English
Published:	Wiley 2017

Similar Items

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
by: Krum, H, et al.
Published: (2010)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Preiss, D, et al.
Published: (2013)

Effect of Valsartan on the Incidence of Diabetes REPLY
by: Holman, R, et al.
Published: (2010)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
by: Preiss, D, et al.
Published: (2012)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Latini, R, et al.
Published: (2013)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
by: Mcmurray, J, et al.
Published: (2011)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
by: Sharma, A, et al.
Published: (2016)

Effect of valsartan on the incidence of diabetes and cardiovascular events.
by: McMurray, J, et al.
Published: (2010)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
by: Dos Santos, M, et al.
Published: (2017)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
by: Bethel, M, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
by: Bethel, M, et al.
Published: (2013)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
by: Haynes, R, et al.
Published: (2018)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
by: Shen, L, et al.
Published: (2012)

Evaluation of a self-administered oral glucose tolerance test
by: Bethel, M, et al.
Published: (2013)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
by: Shen, L, et al.
Published: (2013)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
by: Bales, C, et al.
Published: (2013)

High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test?
by: Bethel, M, et al.
Published: (2008)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
by: Holman, R, et al.
Published: (2003)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
by: McMurray, J, et al.
Published: (2012)

Determining the most appropriate components for a composite clinical trial outcome.
by: Bethel, M, et al.
Published: (2008)

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
Published: (2008)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
by: Gerstein, H, et al.
Published: (2006)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
by: McMurray, J, et al.
Published: (2004)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
by: Wamil, M, et al.
Published: (2020)

Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2019)

The authors reply
by: Holman, R, et al.
Published: (2010)

Angiotensin II receptor blocker valsartan enhances glucose-induced insulin secretion
by: Ayob, Azizi, et al.
Published: (2006)

Expert Workshop on Impaired Glucose Tolerance Held in London, UK - 29 March 1995 - Introduction
by: Holman, R
Published: (1996)

Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2021)

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
by: Holman, R, et al.
Published: (2017)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
by: Mcmurray, J, et al.
Published: (2012)

Comparison of in vivo tests for glucose tolerance in subjects with normal, impaired glucose tolerance and type 2 diabetes
by: Hermans, M, et al.
Published: (1996)

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach
by: Theodorakis, M, et al.
Published: (2016)

Early detection of impaired glucose tolerance in young adults
by: May, Khin Soe, et al.
Published: (2013)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
by: Bethel, A, et al.
Published: (2005)

Evaluation of a self-administered oral glucose tolerance test.
by: Bethel, M, et al.
Published: (2013)